Market Overview:
The global viral vector manufacturing market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing demand for gene therapy and vaccines, and the rising number of approvals for viral vector-based therapeutics. Based on type, the global viral vector manufacturing market is segmented into adenoviral vectors, adeno-associated viral vectors (AAV), retroviral vectors, lentiviral vectors, and other types. Adenoviral vectors are further classified into human adenovirus (HAdV) and nonhuman adenovirus (NHAdV). AAVs are further classified into recombinant AAVs (rAAVs) and helper-dependent AAVs (HD-AAVs). Lentiviral vectors are also subclassified into self-inactivating lentiviral particles (SILPs) and replication competent lentiviruses (RCLVs). Based on application, the global viral vector manufacturing market is segmented into gene therapy and vaccinology. Geographically, the global viral vector manufacturing market is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
A viral vector is a virus that has been genetically modified to carry a foreign gene into a host cell. The vector can then infect other cells and replicate, spreading the new gene. Viral vectors are important tools for genetic engineering and gene therapy. They can be used to insert genes into cells to correct genetic defects or to treat diseases by delivering therapeutic genes directly to tumor cells.
Adenoviral Vectors:
Adenoviral vectors are used to carry and inject the DNA or RNA of a gene into cells. Adenovirus is a virus that causes the common cold. It can also be used for gene therapy, research, and as an animal model in studies related to human diseases.
Adeno-associated Viral Vectors:
Adeno-associated viral vectors (AAV) are genetically engineered viruses that can infect and replicate within the cells of many human diseases such as cancer, brain aneurysm, etc. The AAV is used in gene therapy for treating these conditions by delivering a normal copy of the genes into the cell.
Application Insights:
Based on application, the market is segmented into gene therapy, vaccine development and immunization, therapeutic vaccination, pre-clinical research & testing and other applications. The gene therapy segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as increasing number of patients suffering from genetic diseases worldwide. For instance, according to data published by the National Center for Biotechnology Information (NCBI) in 2015; there are more than 60 million people with rare diseases worldwide.
The vaccine development and immunization segment is expected to witness lucrative growth over the forecast period owing to increase government funding for new vaccines against various infectious diseases including HIV/AIDS, tuberculosis (TB), dengue fever virus infection among others. Furthermore, growing awareness about preventive healthcare measures along with rising incidences of infectious disease globally is anticipated to boost demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of biopharmaceutical companies engaged in viral vector research and development. Moreover, increasing investment by these companies for manufacturing adenovirus, adeno-associated virus (AAV), and retroviral vectors is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising investments by governments as well as non-profit organizations for improving healthcare infrastructure in emerging countries such as China and India. In addition, growing awareness regarding various advanced treatment options provided by gene therapy clinics will boost demand further over this period. Furthermore, an increase in approvals for new products across several Asian countries will fuel demand during this time frame (For example; New Zealand’s Medicines & Medical Devices Evaluation Agency approved AAVrh10b2 vector developed by Sosei Heptares Inc.).
Growth Factors:
- Increasing demand for gene therapy and regenerative medicine
- Growing prevalence of chronic diseases
- Rising public and private investment in viral vector manufacturing technology
- Advances in biotechnology and nanotechnology
- Proliferation of contract research organizations
Scope Of The Report
Report Attributes
Report Details
Report Title
Viral Vector Manufacturing Market Research Report
By Type
Adenoviral Vectors, Adeno-associated Viral Vectors, Retroviral Vectors, Lentiviral Vectors, Other
By Application
Gene Therapy, Vaccinology
By Companies
BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, FUJIFILM Diosynth Biotechnologies, Lonza, Biovian, Thermo Fisher Scientific (Brammer Bio)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Viral Vector Manufacturing Market Report Segments:
The global Viral Vector Manufacturing market is segmented on the basis of:
Types
Adenoviral Vectors, Adeno-associated Viral Vectors, Retroviral Vectors, Lentiviral Vectors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gene Therapy, Vaccinology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioReliance
- Cobra Biologics
- Oxford BioMedica
- UniQure
- FinVector
- MolMed
- MassBiologics
- FUJIFILM Diosynth Biotechnologies
- Lonza
- Biovian
- Thermo Fisher Scientific (Brammer Bio)
Highlights of The Viral Vector Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Retroviral Vectors
- Lentiviral Vectors
- Other
- By Application:
- Gene Therapy
- Vaccinology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viral Vector Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Viral vector manufacturing is a process of creating a virus using genetic engineering. Viruses are used to carry genes into cells, where they can be inserted and replicated. This technology can be used to create new drugs or vaccines, or to improve existing ones.
Some of the major players in the viral vector manufacturing market are BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, FUJIFILM Diosynth Biotechnologies, Lonza, Biovian, Thermo Fisher Scientific (Brammer Bio).
The viral vector manufacturing market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viral Vector Manufacturing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viral Vector Manufacturing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viral Vector Manufacturing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viral Vector Manufacturing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viral Vector Manufacturing Market Size & Forecast, 2020-2028
4.5.1 Viral Vector Manufacturing Market Size and Y-o-Y Growth
4.5.2 Viral Vector Manufacturing Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adenoviral Vectors
5.2.2 Adeno-associated Viral Vectors
5.2.3 Retroviral Vectors
5.2.4 Lentiviral Vectors
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Gene Therapy
6.2.2 Vaccinology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Viral Vector Manufacturing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viral Vector Manufacturing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adenoviral Vectors
9.6.2 Adeno-associated Viral Vectors
9.6.3 Retroviral Vectors
9.6.4 Lentiviral Vectors
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Gene Therapy
9.10.2 Vaccinology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adenoviral Vectors
10.6.2 Adeno-associated Viral Vectors
10.6.3 Retroviral Vectors
10.6.4 Lentiviral Vectors
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Gene Therapy
10.10.2 Vaccinology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adenoviral Vectors
11.6.2 Adeno-associated Viral Vectors
11.6.3 Retroviral Vectors
11.6.4 Lentiviral Vectors
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Gene Therapy
11.10.2 Vaccinology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adenoviral Vectors
12.6.2 Adeno-associated Viral Vectors
12.6.3 Retroviral Vectors
12.6.4 Lentiviral Vectors
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Gene Therapy
12.10.2 Vaccinology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adenoviral Vectors
13.6.2 Adeno-associated Viral Vectors
13.6.3 Retroviral Vectors
13.6.4 Lentiviral Vectors
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Gene Therapy
13.10.2 Vaccinology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Viral Vector Manufacturing Market: Competitive Dashboard
14.2 Global Viral Vector Manufacturing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BioReliance
14.3.2 Cobra Biologics
14.3.3 Oxford BioMedica
14.3.4 UniQure
14.3.5 FinVector
14.3.6 MolMed
14.3.7 MassBiologics
14.3.8 FUJIFILM Diosynth Biotechnologies
14.3.9 Lonza
14.3.10 Biovian
14.3.11 Thermo Fisher Scientific (Brammer Bio)
